Miller RE - Search Results

1

Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?

Miller RE, Crusz SM, Ledermann JA. Miller RE, et al. Future Oncol. 2019 Jun;15(16):1845-1853. doi: 10.2217/fon-2019-0057. Epub 2019 Apr 30. Future Oncol. 2019. PMID: 31037967

2

The current state of pemetrexed in ovarian cancer.

Miller RE, Banerjee S. Miller RE, et al. Expert Opin Investig Drugs. 2013 Sep;22(9):1201-10. doi: 10.1517/13543784.2013.820703. Epub 2013 Jul 31. Expert Opin Investig Drugs. 2013. PMID: 23899335 Review.

3

Chemotherapy for metastatic castrate-sensitive prostate cancer.

Miller RE, Sweeney CJ. Miller RE, et al. Prostate Cancer Prostatic Dis. 2016 Jun;19(2):139-44. doi: 10.1038/pcan.2016.10. Epub 2016 Mar 15. Prostate Cancer Prostatic Dis. 2016. PMID: 26976365 Review.

4

Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.

Kristeleit RS, Miller RE, Kohn EC. Kristeleit RS, et al. Among authors: miller re. Am Soc Clin Oncol Educ Book. 2016;35:e259-68. doi: 10.1200/EDBK_159086. Am Soc Clin Oncol Educ Book. 2016. PMID: 27249731 Free article. Review.

5

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.

Miller RE, Ledermann JA. Miller RE, et al. Clin Adv Hematol Oncol. 2016 Aug;14(8):619-27. Clin Adv Hematol Oncol. 2016. PMID: 27487106 Review.

6

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.

Miller RE, Ledermann JA. Miller RE, et al. Clin Adv Hematol Oncol. 2016 Sep;14(9):704-11. Clin Adv Hematol Oncol. 2016. PMID: 27673289 Review.

7

The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers.

Miller RE, Ledermann JA. Miller RE, et al. Gynecol Oncol. 2017 Jan;144(1):8-10. doi: 10.1016/j.ygyno.2016.11.040. Epub 2016 Nov 27. Gynecol Oncol. 2017. PMID: 27903404 No abstract available.

8

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CRS Collaborative Network (Supplementary 1); Singh N. Cohen PA, et al. Gynecol Oncol. 2019 Aug;154(2):441-448. doi: 10.1016/j.ygyno.2019.04.679. Epub 2019 May 19. Gynecol Oncol. 2019. PMID: 31118141 Free article. Review.

9

Targeted therapies in gynaecological cancers.

Crusz SM, Miller RE. Crusz SM, et al. Among authors: miller re. Histopathology. 2020 Jan;76(1):157-170. doi: 10.1111/his.14009. Histopathology. 2020. PMID: 31846530 Review.

10

Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.

Lord R, Rauniyar J, Morris T, Condon O, Jones R, Miller R, Hall M, Lofts F, Glasspool RM, Hudson E. Lord R, et al. Int J Gynecol Cancer. 2020 Jul;30(7):1026-1033. doi: 10.1136/ijgc-2019-000973. Epub 2020 Apr 21. Int J Gynecol Cancer. 2020. PMID: 32321768

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

720 results

Search Page